Since it has been shown that CD38 is an important prognostic marker also in DLBCL [82], preclinical studies evaluating efficacy of anti-CD38 mAbs like daratumumab in DLBCL are undertaken. The gene discussed is CD38; the disease is diffuse large B-cell lymphoma.